Eesti -
eesti -
Ravimiamet
enzalutamide norameda pehmekapsel
norameda uab - ensalutamiid - pehmekapsel - 40mg 112tk; 40mg 120tk; 40mg 28tk
Eesti -
eesti -
Ravimiamet
enzalutamide sandoz õhukese polümeerikattega tablett
sandoz pharmaceuticals d.d. - ensalutamiid - õhukese polümeerikattega tablett - 80mg 14tk
Eesti -
eesti -
Ravimiamet
enzalutamide sandoz õhukese polümeerikattega tablett
sandoz pharmaceuticals d.d. - ensalutamiid - õhukese polümeerikattega tablett - 40mg 112tk
Euroopa Liit -
eesti -
EMA (European Medicines Agency)
xtandi
astellas pharma europe b.v. - ensalutamiid - eesnäärmevähk - endokriinset ravi - xtandi is indicated for:the treatment of adult men with metastatic hormone-sensitive prostate cancer (mhspc) in combination with androgen deprivation therapy (see section 5. the treatment of adult men with high-risk non-metastatic castration-resistant prostate cancer (crpc) (see section 5. the treatment of adult men with metastatic crpc who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated (see section 5. the treatment of adult men with metastatic crpc whose disease has progressed on or after docetaxel therapy.